Assessing the cost effectiveness of NSAID: an international perspective

dc.contributorUniversidade Federal de São Paulo (UNIFESP)
dc.contributorMCMASTER UNIV
dc.creatorDrummond, M.
dc.creatorFerraz, M. B.
dc.creatorMason, J.
dc.date.accessioned2018-06-15T18:11:17Z
dc.date.accessioned2022-10-07T20:35:20Z
dc.date.available2018-06-15T18:11:17Z
dc.date.available2022-10-07T20:35:20Z
dc.date.created2018-06-15T18:11:17Z
dc.date.issued1995-07-01
dc.identifierJournal Of Rheumatology. Toronto: J Rheumatol Publ Co, v. 22, n. 7, p. 1408-1411, 1995.
dc.identifier0315-162X
dc.identifierhttp://repositorio.unifesp.br/11600/44649
dc.identifierWOS:A1995RG24600040
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/4019767
dc.description.abstractA number of factors may affect the cost effectiveness of treatments and can cause this to vary by location. These factors include the patient population, relative price levels, clinical practice patterns and incentives to health professionals and institutions such as hospitals. This paper illustrates these issues by assessing the relative cost effectiveness of 3 nonsteroidal antiinflammatory drugs (NSAID), with different levels of gastrointestinal side effects, in 3 countries. We conclude that the relative cost effectiveness of drugs is not only dependent on drug price but may also vary by country.
dc.languageeng
dc.publisherJ Rheumatol Publ Co
dc.relationJournal Of Rheumatology
dc.rightsAcesso restrito
dc.subjectCOST-BENEFIT ANALYSIS
dc.subjectCLINICAL TRIALS
dc.subjectOUTCOME ASSESSMENT
dc.subjectNONSTEROIDAL ANTIINFLAMMATORY DRUGS
dc.titleAssessing the cost effectiveness of NSAID: an international perspective
dc.typeArtigo


Este ítem pertenece a la siguiente institución